TY - JOUR T1 - A Case of <sup>177</sup>Lu-DOTATATE Therapy Without the Use of Antiemetics JF - Journal of Nuclear Medicine Technology JO - J. Nucl. Med. Technol. SP - 354 LP - 355 DO - 10.2967/jnmt.121.261996 VL - 49 IS - 4 AU - Justin G. Peacock AU - Brendan O’Sullivan AU - Michael R. Povlow Y1 - 2021/12/01 UR - http://tech.snmjournals.org/content/49/4/354.abstract N2 - Recommended 177Lu-DOTATATE treatment regimens involve prophylaxis with antiemetics to counteract the emetogenic properties of the nephroprotective amino acid solution infusion. We describe a 58-y-old woman treated with 177Lu-DOTATATE for metastatic small-bowel carcinoid, who was allergic to many classes of antiemetics. Therefore, she was treated with 177Lu-DOTATATE without antiemetic prophylaxis. She tolerated the compounded amino acid infusion of lysine and arginine, followed by 177Lu-DOTATATE, without significant nausea or any vomiting. We hypothesize that aggressive antiemetic prophylaxis may not be necessary if a 177Lu-DOTATATE patient receives compounded lysine/arginine amino acid solutions. The omission would decrease overall health-care costs and limit possible medication side effects. ER -